Treatment for Dyskinesia in Parkinson's Disease: A Network Meta‐analysis of Randomized Controlled Trials
Movement Disorders · 2025-05 · 40 (5) · 869-880
DOI: 10.1002/mds.30179 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Movement Disorders, online erschienen am 18.03.2025. Verfasst von Rui Yan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Center for Movement Disorders, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Antiparkinson Agents, Deep Brain Stimulation, Dyskinesia, Drug-Induced, Levodopa. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: National Natural Science Fundation of China.
Abstract (Originalsprache)
Background
Dyskinesia is a motor complication of Parkinson's disease (PD) posing therapeutic challenges. The optimal therapy for dyskinesia in PD has not been identified due to the lack of comprehensive evaluation of treatments.
Objective
The aim was to compare the efficacy and safety of interventions for alleviating levodopa‐induced dyskinesia in PD.
Methods
We conducted a Bayesian network meta‐analysis (NMA) by systematically searching PubMed, Web of Science, Embase, Cochrane Library, ClinicalTrials.gov , and EudraCT databases up to April 1, 2024. The primary efficacy outcome was the change in scores on dyskinesia rating scales from baseline.
Results
The study included 85 randomized controlled trials (RCT) involving 13,826 PD patients, comprising 39 interventions. Nine treatments were significantly more effective in reducing scores on dyskinesia rating scales than control (placebo, sham surgery, sham repetitive transcranial magnetic stimulation, or best medical treatment). Globus pallidus interna deep brain stimulation (GPi‐DBS) had the highest probability to be the most effective (standardized mean difference, 95% credible interval: −1.27, −1.65 to −0.88; surface under the cumulative ranking curve [SUCRA]: 97.4%), followed by levodopa–carbidopa intestinal gel infusion (SUCRA = 89.7%), subthalamic nucleus (STN)‐DBS (SUCRA = 89%), immediate‐release (IR) amantadine (SUCRA = 86.5%), pallidotomy (SUCRA = 84.9%), ADS‐5102 (SUCRA = 82.9%), clozapine (SUCRA = 77.2%), OS320 (SUCRA = 64.8%), and AFQ056 (SUCRA = 54.5%). GPi‐DBS was superior to STN‐DBS, and pallidotomy ranked higher than subthalamotomy. ADS‐5102 and OS320 had higher adverse event (AE) rates compared to control, whereas AFQ056 and ADS‐5102 were linked to more serious AEs.
Conclusions
This RCT‐based NMA identifies and ranks nine efficacious interventions for dyskinesia in PD. GPi‐DBS may be the most effective therapy for treating dyskinesia, with IR amantadine ranking highest among oral medications. Novel anti‐dyskinetic medications are associated with less‐favorable tolerance profiles. © 2025 International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Center for Movement Disorders, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- China National Clinical Research Center for Neurological Diseases, Beijing, China.
- Department of Neurology, Aerospace Center Hospital, Beijing, China.
ORCID-Profile: Tao Feng
Förderung
- National Natural Science Fundation of China
Zitieren
APA
Yan, R., Zheng, X., Yin, Y., Zhang, J., Cui, Y., Su, D., Wan, Z., & Feng, T. (2025). Treatment for Dyskinesia in Parkinson's Disease: A Network Meta‐analysis of Randomized Controlled Trials. Movement Disorders, 40(5), 869-880. https://doi.org/10.1002/mds.30179
Vancouver
Yan R, Zheng X, Yin Y, Zhang J, Cui Y, Su D, et al. Treatment for Dyskinesia in Parkinson's Disease: A Network Meta‐analysis of Randomized Controlled Trials. Movement Disorders. 2025;40(5):869-880. doi:10.1002/mds.30179
BibTeX
@article{Yan2025,
author = {Yan, Rui and Zheng, Xiaoqing and Yin, Yixuan and Zhang, Junjiao and Cui, Yusha and Su, Dongning and Wan, Zhirong and Feng, Tao},
title = {Treatment for Dyskinesia in Parkinson's Disease: A Network Meta‐analysis of Randomized Controlled Trials},
journal = {Movement Disorders},
year = {2025},
volume = {40},
number = {5},
pages = {869--880},
doi = {10.1002/mds.30179}
}
EUVIMED